A SARMOUNT-5 phase 3b clinical study depicts that tirzepatide reduced body weight by 20.2% of the initial weight
According to a report from the WHO, in 2022, ~830 million people worldwide had diabetes, and over 95% of diabetes cases are type 2
This flat-rate pricing makes long-term treatment predictable and sustainable for most patients seeking weight loss with dietary flexibility
Id add, further upstream from that, as community members, advocate, promote, and share with policymakers, the community factors that could prevent obesity, and its chronic diseases
I believe it's time for a balanced, science-based regulatory framework that includes: Rigorous manufacturing standards Expanded clinical research Ongoing safety monitoring Responsible physician oversight Risk-based evaluation of individual peptides Patients deserve access to evidence-based innovation
however, it is unclear whether intracellular GSH production by tumours themselves is required